Could ADHD drugs be the answer to menopausal brain fog? A new scoping review found that lisdexamfetamine (Vyvanse) and atomoxetine (Strattera) significantly improved self-reported executive function in perimenopausal women without prior ADHD diagnoses. Experts say the findings are exciting but preliminary — larger trials are needed before these drugs can be recommended for this use.
Between 44% and 60% of perimenopausal women experience "brain fog" — trouble concentrating, forgetfulness, and disorganization — and right now, there are no FDA-approved treatments for it. A new scoping review presented at The Menopause Society's annual meeting suggests ADHD medications might help, and the rationale is rooted in brain chemistry: as estrogen declines during menopause, so do dopamine and norepinephrine — the same neurotransmitters implicated in ADHD.
Researchers from the University of Tennessee Health Science Center analyzed five studies involving women aged 45–60. Three randomized controlled trials (60 patients total) tested lisdexamfetamine and atomoxetine against placebo, while two large cross-sectional studies from Iceland and the U.K. (6,048 patients) explored the link between ADHD symptom severity and menopausal burden. Notably, neither drug improved objective cognitive test scores, and the RCT data came from a single research group — so these findings are hypothesis-generating, not practice-changing.
By the Numbers:
Why it matters: The overlap between ADHD and menopausal cognitive symptoms is real and underexplored. Experts say larger, independent trials — including comparisons with menopausal hormone therapy — are urgently needed to give clinicians better tools for one of menopause's most disruptive and commonly overlooked complaints.
